Cardiol Therapeutics Inc Class A (CRDL)
Toronto Exchange · Canada · prices in CAD · close of 19 Oct 2026
Key indicators
| Last close | CAD 1.570 |
|---|---|
| 52-week range | 1.225 – 3.230 |
| Return, 1 month / 3 months | −40.5% / −7.1% |
| Return, 1 year / 3 years | +7.5% / +42.7% |
| Trend | Below its 200-day average |
| RSI (14) | 18 |
| Volatility (1 year) | 63.2% |
| Worst drawdown (1 year) | -50.3% |
| Average daily value traded | 0.62M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cardiol Therapeutics is a clinical-stage biotechnology company based in Canada that develops pharmaceutical formulations of cannabidiol for cardiovascular disease. Its work centres on a purified cannabidiol product candidate being studied for conditions such as heart failure and myocarditis, along with earlier-stage research into other cannabinoid-derived medicines. The company's customers and collaborators are the clinical investigators, hospitals and research institutions that take part in its studies, rather than consumers buying cannabis products.
The shares are listed on the Toronto Exchange in Canada under the code CRDL, and the price on this page is in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cardiol Therapeutics Inc Class A (CRDL) trades on the Toronto Exchange in Canada. It last closed at CAD 1.570 on 19 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 604 of 868 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.5% and over the last three months it fell 7.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Toronto Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 46 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -12.9% | ||
| From 52-week high | -50.3% | ||
| Momentum | 47 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.1% | ||
| 6-month return | -23.8% | ||
| 12-month return, skipping the last month | 80.8% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 63.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.3% | ||
| Liquidity | 48 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.62M CAD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −11.8% |
|---|---|
| 1 month | −40.5% |
| 3 months | −7.1% |
| 6 months | −23.8% |
| 1 year | +7.5% |
| 3 years | +42.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 2.426 / 1.803 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.130 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Toronto Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.